林可霉素生物合成及其分子调控研究进展

林可霉素(lincomycin)是由林可链霉菌(Streptomyces lincolnensis)产生的酰胺类抗生素，在临床上主要用于治疗革兰氏阳性菌引起的感染。鉴于其具有高药用价值和经济价值，林可霉素生物合成和分子调控备受关注，并取得了较好的研究进展。本文综述了林可霉素的特征结构和生物合成，并重点介绍了林可链霉菌中林可霉素的分子调控机制等方面的研究进展，有利于深入认识林可链霉菌次级代谢调控网络，为在林可霉素高产菌中改造调控因子或其靶点元件提高产量提供理论指导。

Biosynthesis and molecular regulation of lincomycin: a review

Lincomycin, an amide antibiotic produced by Streptomyces lincolnensis, is mainly used to treat infections caused by Gram-positive bacteria in clinical practice. In view of its high medicinal value and economic value, progress has been achieved in the biosynthesis and molecular regulation of lincomycin. This review introduces the structural features and biosynthesis of lincomycin, and summarizes the research progress in the molecular regulatory mechanism of lincomycin in S. lincolnensis. The review is conducive to the in-depth understanding of the secondary metabolic regulatory network of S. lincolnensis and provides theoretical guidance for the transformation of regulatory factors or their target elements in the strains with high yields of lincomycin.